GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Regulators in the EU, China, and Japan have started reviews of GSK's depemokimab, aiming to become the first drug for severe asthma that can be given just twice a year. The EMA and counterparts in ...

A new asthma treatment, depemokimab, has shown promise in reducing exacerbations while maintaining a strong safety profile, according to findings presented at the 2025 American Academy of Allergy, ...

With these trends in view, let’s look at the 7 most undervalued biotech stocks to invest in.

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

GlaxoSmithKline and Sigma-tau. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the ...